MED3000 - Novel topical treatment for erectile dysfunction
Lead product, MED3000 is approved as a medical device in the EU and was launched in March and April 2023 in certain countries in Europe with more countries to follow. It becomes the first clinically proven, pan-European OTC topical treatment for erectile dysfunction available without a doctor’s prescription.
The EU authorisation paves the way for approval in many countries around the world, including in Latin America, the Middle East, Africa and the Far East regions, with many countries considering “fast-track" review based on recognition of the EU CE mark. Marketing authorisation has now been received in five Middle Eastern countries with more to follow.
MED3000 is a unique and highly differentiated easy to use topical gel for erectile dysfunction which has Phase 3 clinical data demonstrating highly statistically significant improvement across all ED severities.
Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by Futura as well as when referring to countries where regulatory approval or commercial distribution agreements have not yet been achieved.
Click here to go to our product website eroxon.com
Click here to go to our commercial partner website www.eroxon.eu
One in five men suffer from erectile dysfunction worldwide1 with around 22 million men suffering ED in the US and 20 million men in the UK, France, Italy, Spain and Germany. Erectile dysfunction (ED) is closely linked to age and a number of co-morbidities such as diabetes and heart disease with the incidence of erectile dysfunction expected to increase to 322 million by 20252. Erectile dysfunction can result from organic or psychological causes and is increasingly affecting younger men who can also suffer from performance anxiety due to social pressure and false expectations from easy access to pornography. Erectile dysfunction can lead to low self-esteem, lack of confidence and depression. The detrimental impact on partners and relationships is well documented and acknowledged by the medical community. The discovery and approval of the PDE5i’s to treat ED over 20 years ago (such as Viagra® and Cialis®) not only revolutionised available treatments for men with ED but also dramatically increased awareness in the general public of this significant problem.
The ED market is a well-established market with sales of ED treatments worth US$3.1 billion in 2020. Despite their success PDE5i’s have certain limitations. Although proven highly efficacious, oral PDE5i’s are not a suitable treatment for many men. They are contraindicated for use with a number of medications such as nitrates, anti-hypertensives and alpha blockers. They generally take significant time to work requiring pre-planning for sexual intercourse. ‘On demand’ oral treatments only starts to work in 30-60 minutes. As a result many men and their partners are dissatisfied with PDE5i’s and it has been estimated that almost 50% discontinue use after one year3. In most countries oral PDE5i’s are only available as a prescription only product which presents too high a barrier for many men who are too embarrassed to seek treatment, for whom the process is not convenient enough or who find the cost of the physician and medicine prohibitive in countries such as the US.
There are clearly significant unmet needs for ED sufferers. In early 2023, Futura personnel, alongside representatives from our commercial partners, attended the European Society for Sexual Medicine Congress in Rotterdam where we presented clinical data on MED3000. We co-hosted an Eroxon® stand and received positive interest from congress attendees who welcomed the new innovation in ED.
US market research conducted in 2022 by IPSOS and commissioned by Futura has confirmed that even with increasing volumes the requirement of a doctor’s prescription remains both an economic and emotional barrier to use: US patients spend between US$600 and US$3,500 per annum on ED treatments, when taking into account both prescription costs and doctors’ visits not covered by insurance4. This reconfirms the significant opportunity that MED3000 represents with OTC availability at a likely retail price in the region of US$5 per dose in the USA.
The key findings of the market research showed that the respondents believed that the product, once approved, would be highly differentiated from existing products. In particular consumers found the speed of onset highly appealing.
We are executing upon our strategic plans to establish a global network of licensing and distribution partners with brand building strength, healthcare credibility, regional infrastructure and marketing expertise in order to make MED3000 a long term profitable and sustainable brand for shareholders. profitable. We have chosen partners who have demonstrated their enthusiasm for MED3000 and for whom its success will be meaningful whilst being firmly focused on our goal of delivering long-term and sustainable value to the Company. The Company has entered into commercial licensing deals in key markets for ED in regions such as the EU, Latin America, the Middle East and South Korea.
In March 2023 MED3000 under the brand name Eroxon® was launched online across Europe marking a milestone for the brand and the Company. This was followed in April 2023 with the first launches in Belgium and the UK in retail pharmacies supported with marketing and promotional advertising, with other countries expected in the coming months.
Following the dossier submission to the US FDA, Futura commenced the search for a US commercial partner through its specialist corporate advisors. Futura has also received a number of enquiries regarding commercialisation opportunities for MED3000 for the key US market, and the Board, along with its specialist corporate advisers, is currently in a process to identify the best potential commercial partner.
Futura is committed to delivering long-term and sustainable value to the Company allowing a long-lasting growth franchise to be built around MED3000 either under the Eroxon® brand or potentially an alternative brand depending on regulatory and commercial circumstances in different markets.
As part of building the commercial proposition for MED3000 and supporting its regulatory approval Futura has developed an illustrative pack that licensing partners can select to use at their discretion.
Click here to visit the Eroxon® parent website
m8 Pharmaceuticals, Inc ("m8"), is a specialty biopharmaceutical company focused on commercialisation in Latin America.
Under the terms of the agreement Futura and m8 will work together to gain marketing authorisation and commercialise MED3000 as a clinically proven treatment for ED available OTC in Brazil and Mexico, the two biggest commercial ED and healthcare markets in Latin America. The agreement is for an initial term of 15 years.
m8 will be responsible for all costs related to the regulatory approval and marketing of the product. Futura will provide reasonable ongoing technical support for OTC product development and commercialisation. Futura will receive payments on all sales of MED3000 from m8, and up to four milestone payments totalling US$8.5 million based on cumulative sales volumes within the initial term.
Swiss-based specialty pharma Company, Labatec Pharma (“Labatec”) is focused on commercialisation in Europe and the Middle East and North Africa (“MENA”) regions, for the rights to exclusively commercialise MED3000 in the GCC region as well as Jordan, Lebanon and Iraq.
Futura is eligible to receive initial upfront payments, as well as undisclosed milestone payments based on regulatory approval. Labatec will pay an agreed price to Futura for the manufacture and supply of MED3000 by Futura’s Contract Manufacturing Organisation (“CMO”), plus royalties on all sales. Labatec is responsible for all local MED3000 development and regulatory costs as well as all launch and marketing expenses. The initial licence agreement term is for eight years with the ability to extend for successive two-year terms by mutual consent.
Menarini Korea Limited (“Menarini”) will exclusively commercialise MED3000 for the treatment of ED in South Korea. A.Menarini Korea Ltd is a wholly owned subsidiary of the Italian-based specialty pharma Company Menarini Group. Menarini Korea possesses the capability to successfully register, launch and commercialise brands in the market, with key strengths in men's health and consumer health, with local teams that have a deep understanding and experience of the South Korean market.
Futura is eligible to receive initial undisclosed upfront payments and under agreement terms, will support Menarini to gain marketing authorisation and commercialise MED3000 for ED in South Korea. Menarini will be responsible for all costs related to the regulatory approval and marketing of the product in the region including a clinical bridging study, if required. Futura will provide reasonable technical support for product development and commercialisation and provide manufactured product from Futura’s CMO at an agreed price.
Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation.
Under the terms of the agreement, Cooper will commercialise MED3000 in the EEA, United Kingdom and Switzerland as a clinically proven, safe and fast-acting treatment for ED available without the need for a doctor's prescription.
Futura will receive an initial upfront payment, as well as undisclosed cumulative sales milestone payments and will manufacture and supply the product (through its CMO) for the EEA, United Kingdom and Switzerland to Cooper. The agreement is for an initial term of five years complying with EU competition law. Futura will remain Legal Manufacturer1 and be responsible for supply of MED3000 through its CMO.